RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Possible acquisitions in California@GOTMONEY- that will be hard to predict as hype will be a factor at some point as well. Once people figure out (by Sunniva demonstrating via supply deals) that the California market is finally open to large players and the head start on scale production of cGMP product it may grow quickly well above what prudent financial analysis would indicate. When one looks at pharmaceutical companies getting involved in the space on a greater scale, Sunniva will consistently be considered as one of the strongest candidates for a takeover, another element of the hype attributable portion of potential SP growth. If Sunniva can generate 40-60 million revenue in 2018 and prior to any attributable revenue from Okanagan facility in Canada, then 2019 could see the 2020/2021 potential trajectory you are alluding to.